Iloperidone is an effective antipsychotic for the prevention of relapse during maintenance treatment of schizophrenia in patients previously stabilized on iloperidone.

The approved dose range of iloperidone for acute treatment is 12–24 mg/day given twice a day; in this relapse-prevention trial, most subjects were treated successfully with a dose between 12 and 16 mg/day.

The adverse event profile for iloperidone in this study was consistent with those in the fixed-dose acute iloperidone studies, showing very low propensity to cause extrapyramidal symptoms or akathisia.